How To Get Started
Given the prevalence of cardiovascular disease, type 2 diabetes, chronic kidney disease, and metabolic syndrome, it seems plausible that GLP1s reduce all-cause mortality
In some patients, particularly those recently starting therapy or experiencing gastrointestinal symptoms, gastric contents may be retained even after appropriate fasting periods
Some patients dont respond to GLP-1 receptor agonists because of genetic variability in the GLP-1 receptor or signaling pathways
Dulaglutide (Trulicity) is FDA-approved for Type 2 diabetes in adolescents age 10 and older
The new drugs, which were originally developed to treat diabetes, are targeting the biology that makes weight so hard to lose and keep off: They dial down hunger in the brain, slow gastric emptying, and improve post-meal insulin signaling